Back to today’s briefing

Story perspectives

Insilico Medicine's ISM5411 Shows Promise for IBD Treatment

1/9/2025

31 4

Summary

Story summary

Insilico Medicine has unveiled promising results from two Phase I studies of ISM5411, a groundbreaking gut-targeted treatment for Inflammatory Bowel Disease (IBD). Conducted in Australia and China, the trials confirmed ISM5411's safety and tolerability, with no serious side effects reported. Excitingly, a Phase 2 study is set to begin in late 2025 for patients battling active ulcerative colitis.

1 of 1

Story summary

Insilico Medicine has unveiled promising results from two Phase I studies of ISM5411, a groundbreaking gut-targeted treatment for Inflammatory Bowel Disease (IBD). Conducted in Australia and China, the trials confirmed ISM5411's safety and tolerability, with no serious side effects reported. Excitingly, a Phase 2 study is set to begin in late 2025 for patients battling active ulcerative colitis.